PreprintArticleVersion 1Preserved in Portico This version is not peer-reviewed
Comparative Short and Long-Term Effectiveness and Safety of Pramipexole and Aripiprazole Augmentation in Treatment Resistant Unipolar Depression. An Observational-Retrospective Study
Version 1
: Received: 19 June 2024 / Approved: 19 June 2024 / Online: 20 June 2024 (00:25:41 CEST)
How to cite:
Tundo, A.; Betro', S.; De Filippis, R.; Felici, R.; Lucangeli, C.; Iommi, M. Comparative Short and Long-Term Effectiveness and Safety of Pramipexole and Aripiprazole Augmentation in Treatment Resistant Unipolar Depression. An Observational-Retrospective Study. Preprints2024, 2024061371. https://doi.org/10.20944/preprints202406.1371.v1
Tundo, A.; Betro', S.; De Filippis, R.; Felici, R.; Lucangeli, C.; Iommi, M. Comparative Short and Long-Term Effectiveness and Safety of Pramipexole and Aripiprazole Augmentation in Treatment Resistant Unipolar Depression. An Observational-Retrospective Study. Preprints 2024, 2024061371. https://doi.org/10.20944/preprints202406.1371.v1
Tundo, A.; Betro', S.; De Filippis, R.; Felici, R.; Lucangeli, C.; Iommi, M. Comparative Short and Long-Term Effectiveness and Safety of Pramipexole and Aripiprazole Augmentation in Treatment Resistant Unipolar Depression. An Observational-Retrospective Study. Preprints2024, 2024061371. https://doi.org/10.20944/preprints202406.1371.v1
APA Style
Tundo, A., Betro', S., De Filippis, R., Felici, R., Lucangeli, C., & Iommi, M. (2024). Comparative Short and Long-Term Effectiveness and Safety of Pramipexole and Aripiprazole Augmentation in Treatment Resistant Unipolar Depression. An Observational-Retrospective Study. Preprints. https://doi.org/10.20944/preprints202406.1371.v1
Chicago/Turabian Style
Tundo, A., Chiara Lucangeli and Marica Iommi. 2024 "Comparative Short and Long-Term Effectiveness and Safety of Pramipexole and Aripiprazole Augmentation in Treatment Resistant Unipolar Depression. An Observational-Retrospective Study" Preprints. https://doi.org/10.20944/preprints202406.1371.v1
Abstract
Background. This study compares the short- and long-term effectiveness and safety of pramipexole augmentation (PA) and aripiprazole augmentation (AA) for unipolar treatment-resistant depression (TRD). Methods. Patients were recruited in a private out-patients clinic specialized in mood disorders. At intake and at each visit depressive and (hypo)manic symptoms, clinical status, and level of functioning were evaluated with appropriate scales. The trend of outcomes was analyzed using mixed-effect linear regression models. Results. The study includes 81 unipolar TRD patients treated with PA and 51 with AA. After 12 and 24 weeks of treatment with PA, the predicted response (64.1% and 76.2%) and remission rates (49.7% and 72.7%) were significantly higher than the predicted response (32.2% and 38.0%) and remission rates (18.9% and 28.1%) for AA. The improvement in psychosocial functioning was significantly greater and faster in PA than in AA. PA showed significant superiority over AA as a maintenance strategy (time spent ill and psychosocial functioning) up to 12 months. No difference in safety was found at each time point. Conclusions. PA could be an alternative option for short and long-term treatment of unipolar TRD, more effective and similar in safety with AA. These preliminary results need confirmation from randomized clinical trials.
Medicine and Pharmacology, Psychiatry and Mental Health
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
,
